Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Gastrointestinal Cancers

26 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Colon
Rectal

VICCGI15122

01/15/2016

Research Use of Human Biospecimens from Colorectal Cancer Patients (Pilot Study)

Basic Science

VICCGI0283

06/01/2002

Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Diagnostic

Liver

VICCGI14124

03/13/2015

PET Imaging of Hepatocellular Carcinoma with 18F-FSPG

Other

Liver

VICCGI1523

07/01/2015

Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Registry

Other

Colon
Rectum

VICCGI99003

08/01/2010

Personalized Prevention of Colorectal Cancer

Other

Colon
Rectal

VICCGI0721

01/09/2007

Vanderbilt Hereditary Colorectal Cancer Registry

Prevention

Colon

GIS0820-M

07/09/2013

A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

Treatment

Bladder
Colon
Gastric/Gastroesophageal
Kidney (Renal Cell)
Rectal
Urologic

VICCGI15126

05/03/2016

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment

Colon
Head/Neck
Liver
Lung
Miscellaneous
Neuro-Oncology
Rectal
Sarcoma
Thyroid

VICCMD15110

04/05/2016

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Treatment

Colon
Rectal

VICCGI1623

03/16/2016

A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes with PINPOINT? Near Infrared Fluorescence Imaging in Low Anterior Resection

Treatment

Colon
Head/Neck
Lung
Lymphoma
Melanoma
Non Small Cell
Ovarian
Rectal

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

Gastric/Gastroesophageal

VICCGI1515

01/05/2016

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

Treatment

Colon
Esophageal
Head/Neck
Lung
Non Small Cell
Rectal

VICCPHI1598

12/10/2015

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Treatment

Bladder
Breast
Colon
Esophageal
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Lung
Melanoma
Non Small Cell
Pancreatic
Rectal
Urologic
Uterine

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

Pancreatic

ECOGGIS1505

11/17/2015

A Randomized Phase II Study of Perioperative Mfolfirinox versus Gemcitabine/NAB-PACLITAXEL as Therapy for Resectable Pancreatic Adenocarcinoma

Treatment

Colon
Esophageal
Gastric/Gastroesophageal
Liver
Pancreatic
Rectal

VICCGIP1536

10/26/2015

A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

Treatment

Bladder
Breast
Hematologic
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic
Urologic

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

Liver

VICCGI1586

07/31/2015

A Humanitarian Device Exemption Treatment Protocol of TheraSphere? for Treatment of Primary Liver Cancer

Treatment

VICCGIP1520

07/21/2015

A Phase 1, Open Label, Non Randomized, Dose Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS 102 in Combination with CPT 11 and Bevacizumab In Patients with Advanced Gastrointestinal Tumors

Treatment

Pancreatic

VICCGI1507

06/16/2015

NAB-PACLITAXEL (ABRAXANE) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)

Treatment

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

Pancreatic

VICCGI1370

12/30/2013

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment

Neuroendocrine
Pancreatic

VICCGI1250

04/09/2013

A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Treatment

Liver

CTSUGI80702-M

05/05/2011

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

Treatment

Liver

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)